Press release - August 4th, 2010
cerbomed announces Prof. Dr. med Jens Ellrich as Chief Medical Officer (CMO)
Erlangen, August 04th, 2010. The neuroscientist Prof. Dr. Jens Ellrich takes over the department “Medical” of cerbomed GmbH, a start-up company in the area of neuromodulation.
Prof. Dr. Ellrich brings a wealth of experience for his new task as CMO, having spent 18 years in the field of neuroscience. As CMO, Prof. Dr. Ellrich will be responsible for the preclinical and clinical development. Next to his position as CMO he will continue his professorship of medical physiology at the University of Aalborg in Denmark, which ensures the contact to the scientific community as well as access to latest research findings. Before joining cerbomed Prof. Dr. Ellrich was head of the “Medical Physiology and Experimental Pharmacology Group“ at the University of Aalborg. Prior to that, he was professor of experimental neurosurgery at the Interdisciplinary Center for Clinical Research at the RWTH Aachen Universtity for four years and supervised the new neuroscientific research group “Pain”. His research focuses on the interface between basic research and its clinical application, especially in terms of neuromodulation and the plasticity of neural signal processing.
Dr. Andreas Hartlep, managing director of cerbomed, sees great potential in the appointment of Prof. Dr. Ellrich as CMO, particularly with regard to upcoming multicenter studies: “We have managed to attract a key specialist in the field of neuroscience and pharmacology. The depth of his medical expertise and his wide network will be valuable input for cerbomed, ranging from clinical research to successful market launch.“
Prof. Dr. Ellrich received his medical degree of neurology and clinical neurophysiology at the University of Mainz. In 2000 he obtained his postdoctoral lecture qualification at the Physiology and Experimental Pathophysiology Institute of the University of Erlangen-Nuremberg. Currently the Göttingen-born is looking forward to his new responsibilities: “My ambition is to transform scientific achievements into market-ready products and to offer new and effective treatment options for patients.”
cerbomed is a young, medical device company focusing on the research, development and manufacturing of innovative technologies and products in the area of neuromodulation. Its major proprietary procedure, transcutaneous vagus nerve stimulation (t-VNS), will offer a new, alternative treatment for various neuropsychiatric disorders with clinical benefit and improved quality of life at a superior cost benefit ratio. Since its foundation in December 2005, cerbomed has received many innovation and new enterprise prices (including university- and chamber of commerce new enterprise awards), and was among the federal winners of the German new enterprise prize in 2006.